Skip to main content
Erschienen in: International Journal of Clinical Oncology 1/2013

01.02.2013 | Original Article

Prognostic factors for patients with solitary bone metastasis

verfasst von: Manabu Hoshi, Jun Takada, Makoto Ieguchi, Shinji Takahashi, Hiroaki Nakamura

Erschienen in: International Journal of Clinical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

The term ‘solitary bone metastasis’ is defined in the present study as a single bone metastasis originating from a primary cancer without visceral organ metastasis. We assessed the survival rates and prognostic factors in 42 patients with solitary bone metastasis, and discussed the impact of different surgical strategies on survival.

Methods

We retrospectively analyzed data from 42 patients (25 male, 17 female) who underwent treatment for solitary bone metastasis at a single institution. The median age of the patients was 64.5 years (range 41–82 years). The patients were followed for an average period of 21.2 months (range 0.4–127.3 months). Their clinical records were retrospectively reviewed. Factors influencing survival were determined using univariate and multivariate analyses; particular attention was paid to the orthopedic surgery used for solitary bone metastasis.

Results

The 1-year survival rate was 76.5%, and the median survival period was 30.0 months. The presence of primary cancer and poor performance status were identified as independent prognostic factors using Cox regression multivariate analysis. Tumor resection and surgical margin were not significantly related to patient survival.

Conclusions

The results of this analysis indicated that the prognosis for patients with solitary bone metastasis depended on the presence of primary cancer and on poor performance status.
Literatur
1.
Zurück zum Zitat Tofe AJ, Francis MD, Harvey WJ (1975) Correlation of neoplasms with incidence and localization of skeletal metastases: an analysis of 1,355 diphosphonate bone scans. J Nucl Med 16:986–989PubMed Tofe AJ, Francis MD, Harvey WJ (1975) Correlation of neoplasms with incidence and localization of skeletal metastases: an analysis of 1,355 diphosphonate bone scans. J Nucl Med 16:986–989PubMed
2.
Zurück zum Zitat Katagiri H, Takahashi M, Wakai K et al (2005) Prognostic factors and a scoring system for patients with skeletal metastasis. J Bone Joint Surg Br 87:698–703PubMedCrossRef Katagiri H, Takahashi M, Wakai K et al (2005) Prognostic factors and a scoring system for patients with skeletal metastasis. J Bone Joint Surg Br 87:698–703PubMedCrossRef
3.
Zurück zum Zitat Tokuhashi Y, Matsuzaki H, Toriyama S et al (1990) Scoring system for the preoperative evaluation of metastatic spine tumor prognosis. Spine 15:1110–1113PubMedCrossRef Tokuhashi Y, Matsuzaki H, Toriyama S et al (1990) Scoring system for the preoperative evaluation of metastatic spine tumor prognosis. Spine 15:1110–1113PubMedCrossRef
4.
Zurück zum Zitat Tomita K, Kawahara N, Kobayashi T et al (2001) Surgical strategy for spinal metastases. Spine 260:298–306CrossRef Tomita K, Kawahara N, Kobayashi T et al (2001) Surgical strategy for spinal metastases. Spine 260:298–306CrossRef
5.
Zurück zum Zitat Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655PubMedCrossRef Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655PubMedCrossRef
6.
Zurück zum Zitat Swenerton KD, Legha SS, Smith T et al (1979) Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39:1552–1562PubMed Swenerton KD, Legha SS, Smith T et al (1979) Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39:1552–1562PubMed
7.
Zurück zum Zitat Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249PubMedCrossRef Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249PubMedCrossRef
8.
9.
Zurück zum Zitat Stanley KE (1980) Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65:25–32PubMed Stanley KE (1980) Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65:25–32PubMed
10.
Zurück zum Zitat Sugiura H, Yamada K, Sugiura T et al (2008) Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res 466:729–736PubMedCrossRef Sugiura H, Yamada K, Sugiura T et al (2008) Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res 466:729–736PubMedCrossRef
11.
Zurück zum Zitat Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237–2246PubMedCrossRef Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237–2246PubMedCrossRef
12.
Zurück zum Zitat Lee DH, Han JY, Lee HG et al (2005) Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res 11:3032–3037PubMedCrossRef Lee DH, Han JY, Lee HG et al (2005) Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res 11:3032–3037PubMedCrossRef
13.
Zurück zum Zitat Schiller JH (2001) Current standards of care in small-cell and non-small-cell lung cancer. Oncology 61:3–13PubMedCrossRef Schiller JH (2001) Current standards of care in small-cell and non-small-cell lung cancer. Oncology 61:3–13PubMedCrossRef
14.
Zurück zum Zitat Cho HS, Oh JH, Han I et al (2009) Survival of patients with skeletal metastases from hepatocellular carcinoma after surgical management. J Bone Joint Surg Br 91:1505–1512PubMedCrossRef Cho HS, Oh JH, Han I et al (2009) Survival of patients with skeletal metastases from hepatocellular carcinoma after surgical management. J Bone Joint Surg Br 91:1505–1512PubMedCrossRef
15.
Zurück zum Zitat He J, Zeng ZC, Tang ZY et al (2009) Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy. Cancer 115:2710–2712PubMedCrossRef He J, Zeng ZC, Tang ZY et al (2009) Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy. Cancer 115:2710–2712PubMedCrossRef
16.
Zurück zum Zitat Chan KM, Yu MC, Wu TJ et al (2009) Efficacy of surgical resection in management of isolated extrahepatic metastases of hepatocellular carcinoma. World J Gastroenterol 15:5481–5488PubMedCrossRef Chan KM, Yu MC, Wu TJ et al (2009) Efficacy of surgical resection in management of isolated extrahepatic metastases of hepatocellular carcinoma. World J Gastroenterol 15:5481–5488PubMedCrossRef
17.
Zurück zum Zitat Fuchs B, Trousdale RT, Rock MG (2005) Solitary bony metastasis from renal cell carcinoma: significance of surgical treatment. Clin Orthop Relat Res 431:187–192PubMedCrossRef Fuchs B, Trousdale RT, Rock MG (2005) Solitary bony metastasis from renal cell carcinoma: significance of surgical treatment. Clin Orthop Relat Res 431:187–192PubMedCrossRef
18.
Zurück zum Zitat Hoshi M, Taguchi S, Hayakawa K et al (2011) Evaluation of clinical problems associated with bone metastases from carcinoma from unknown primary site. Arch Orthop Trauma Surg 131:59–64PubMedCrossRef Hoshi M, Taguchi S, Hayakawa K et al (2011) Evaluation of clinical problems associated with bone metastases from carcinoma from unknown primary site. Arch Orthop Trauma Surg 131:59–64PubMedCrossRef
19.
Zurück zum Zitat Pavlidis N, Briasoulis E, Hainsworth J et al (2003) Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39:1990–2005PubMedCrossRef Pavlidis N, Briasoulis E, Hainsworth J et al (2003) Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39:1990–2005PubMedCrossRef
20.
Zurück zum Zitat Yazawa Y, Frassica FJ, Chao EY et al (1990) Metastatic bone disease. A study of the surgical treatment of 166 pathologic humeral and femoral fractures. Clin Orthop Relat Res 251:213–219PubMed Yazawa Y, Frassica FJ, Chao EY et al (1990) Metastatic bone disease. A study of the surgical treatment of 166 pathologic humeral and femoral fractures. Clin Orthop Relat Res 251:213–219PubMed
21.
Zurück zum Zitat Lin PP, Mirza AN, Lewis VO et al (2007) Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am 89:1794–1800PubMedCrossRef Lin PP, Mirza AN, Lewis VO et al (2007) Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am 89:1794–1800PubMedCrossRef
22.
Zurück zum Zitat Takashi M, Takagi Y, Sakata T et al (1995) Surgical treatment of renal cell carcinoma metastases: prognostic significance. Int Urol Nephrol 27:1–8PubMedCrossRef Takashi M, Takagi Y, Sakata T et al (1995) Surgical treatment of renal cell carcinoma metastases: prognostic significance. Int Urol Nephrol 27:1–8PubMedCrossRef
23.
Zurück zum Zitat Jung ST, Ghert MA, Harrelson JM et al (2003) Treatment of osseous metastases in patients with renal cell carcinoma. Clin Orthop Relat Res 409:223–231PubMedCrossRef Jung ST, Ghert MA, Harrelson JM et al (2003) Treatment of osseous metastases in patients with renal cell carcinoma. Clin Orthop Relat Res 409:223–231PubMedCrossRef
24.
Zurück zum Zitat Dürr HR, Müller PE, Lenz T et al (2002) Surgical treatment of bone metastases in patients with breast cancer. Clin Orthop Relat Res 396:191–196PubMedCrossRef Dürr HR, Müller PE, Lenz T et al (2002) Surgical treatment of bone metastases in patients with breast cancer. Clin Orthop Relat Res 396:191–196PubMedCrossRef
Metadaten
Titel
Prognostic factors for patients with solitary bone metastasis
verfasst von
Manabu Hoshi
Jun Takada
Makoto Ieguchi
Shinji Takahashi
Hiroaki Nakamura
Publikationsdatum
01.02.2013
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 1/2013
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-011-0359-3

Weitere Artikel der Ausgabe 1/2013

International Journal of Clinical Oncology 1/2013 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.